CGEN Compugen

USD 2.54 0.04 1.6
Icon

Compugen (CGEN) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.54

+0.04 (+1.60)%

USD 0.24B

0.31M

USD 4.50(+77.17%)

N/A

Icon

CGEN

Compugen (USD)
COMMON STOCK | NSD
USD 2.54
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.24B

N/A

USD 2.54

Compugen (CGEN) Stock Forecast

Show ratings and price targets of :
USD 4.50
(+77.17%)

Based on the Compugen stock forecast from 2 analysts, the average analyst target price for Compugen is USD 4.50 over the next 12 months. Compugen’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Compugen is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Compugen’s stock price was USD 2.54. Compugen’s stock price has changed by -5.58% over the past week, -4.15% over the past month and +250.44% over the last year.

No recent analyst target price found for Compugen
No recent average analyst rating found for Compugen

Company Overview Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody t...Read More

https://cgen.com

Azrieli Center, Holon, Israel, 5885849

68

December

USD

USA

Adjusted Closing Price for Compugen (CGEN)

Loading...

Unadjusted Closing Price for Compugen (CGEN)

Loading...

Share Trading Volume for Compugen Shares

Loading...

Compare Performance of Compugen Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for CGEN

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Compugen (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing CGEN

Symbol Name CGEN's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Compugen (CGEN) Stock

Based on ratings from 2 analysts Compugen's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.

Unfortunately we do not have enough data on CGEN's stock to indicate if its a good dividend stock.

Based on targets from 2 analysts, the average taret price for CGEN is USD 4.50 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 4.

Unfortunately we do not have enough data on CGEN's stock to indicate if its overvalued.

The last closing price of CGEN's stock was USD 2.54.

The most recent market capitalization for CGEN is USD 0.24B.

Based on targets from 2 analysts, the average taret price for CGEN is projected at USD 4.50 over the next 12 months. This means that CGEN's stock price may go up by +77.17% over the next 12 months.

We can't find any ETFs which contains Compugen's stock.

As per our most recent records Compugen has 68 Employees.

Compugen's registered address is Azrieli Center, Holon, Israel, 5885849. You can get more information about it from Compugen's website at https://cgen.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...